Page 1500 - Williams Hematology ( PDFDrive )

1474 Part X: Malignant Myeloid Diseases Chapter 89: Chronic Myelogenous Leukemia and Related Disorders 1475

90. Strife A, Clarkson B: Biology of chronic myelogenous leukemia: Is discordant matura- 118. Cashman JD, Eaves CJ, Sarris AH, Eaves AC: MCP-1, not MIP-1α, is the endogenous
tion the primary defect? Semin Hematol 25:1, 1988. chemokine that cooperates with TGF-β to inhibit the cycling of primitive normal
91. Heinzinger M, Waller CF, Rosentiel A, et al: Quality of IL-3 and G-CSF-mobilized but not leukemic (CML) progenitors in long-term human marrow cultures. Blood
peripheral blood stem cells in patients with early chronic phase CML. Leukemia 92:2338, 1998.
12:333, 1998. 119. Murohashi I, Endho K, Nishida S, et al: Differential effects of TGF-beta 1 on normal
92. Verfaillie CM, Bhatia R, Miller W, et al: BCR/ABL-negative primitive progenitors suit- and leukemic human hematopoietic cell proliferation. Exp Hematol 23:970, 1995.
able for transplantation can be selected from the marrow of most early-chronic phase 120. Gordon MY, Dowding C, Riley G, et al: Altered adhesive interactions with marrow
but not accelerated-phase chronic myelogenous leukemia patients. Blood 87:4770, 1996. stroma of haematopoietic progenitor cells in chronic myeloid leukaemia. Nature
93. Grand FH, Marley SB, Chase A, et al: BCR/ABL-negative progenitors are enriched in 328:342, 1987.
the adherent fraction of CD34+ cells circulating in the blood of chronic phase chronic 121. Bhatia R, Wayner EA, McGlave PB, Verfaillie CM: Interferon-α restores normal adhe-
myeloid leukemia patients. Leukemia 11:1486, 1997. sion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow
94. Carella AM, Podesta M, Frassoni R, et al: Collection of “normal” blood repopulating stroma by correcting impaired β1 integrin receptor function. J Clin Invest 94:384, 1994.
cells during early hemopoietic recovery after intensive conventional chemotherapy in 122. Verfaillie CM: Stem cells in chronic myelogenous leukemia. Hematol Oncol Clin North
chronic myelogenous leukemia. Bone Marrow Transplant 12:267, 1993. Am 11:1079, 1997.
95. Guyootat D, Wahabi K, Viallet A, et al: Selection of BCR/ABL-negative stem cells 123. Bhatia R, Munthe HA, Verfaillie CM: Tyrphostin AG957, a tyrosine kinase inhibi-
from marrow or blood of patients with chronic myeloid leukemia. Leukemia 13:991, tor with anti-BCR/ABL tyrosine activity restores β integrin-mediated adhesion and
1
1999. inhibiting signaling in chronic myelogenous leukemia hematopoietic progenitors.
96. Hogge DE, Coulumbel L, Kalousek D, et al: Nonclonal hemopoietic progenitors in Leukemia 12:1708, 1998.
a G6PD heterozygote with chronic myelogenous leukemia revealed after long-term 124. Lundell BI, McCarthy JB, Kovach NL, Verfaillie CM: Activation of beta 1 integrins
marrow culture. Am J Hematol 24:389, 1987. on CML progenitors reveals cooperation between beta1 integrins and CD44 in the
97. Delforge M, Boogaerts MA, McGlave PB, Verfaillie CM: BCR/ABL-CD34+HLA-DR− regulation of adhesion and proliferation. Leukemia 11:822, 1997.
progenitor cells in early phase, but not in more advanced phases, of chronic myeloge- 125. Vijayan KV, Advani SH, Zingde SM: Chronic myeloid leukemic granulocytes exhibit
nous leukemia are polyclonal. Blood 93:284, 1999. reduced and altered binding to P-selectin; modification in the CD15 antigens and
98. Van den Berg D, Wessman M, Murray L, et al: Leukemic burden in subpopulations of sialylation. Leuk Res 21:59, 1997.
CD34+ cells isolated from the mobilized peripheral blood of alpha-interferon-resistant 126. Deininger MW, Vieira S, Mendiola R, et al: BCR-ABL tyrosine kinase activity regu-
or -intolerant patients with chronic myeloid leukemia. Blood 87:4348, 1996. lates the expression of multiple genes implicated in the pathogenesis of chronic mye-
99. Podesta M, Piaggio G, Frassoni F, et al: Very primitive hemopoietic cells (LTC-IC) loid leukemia. Cancer Res 60:2049, 2000.
are present in Philadelphia negative cytaphereses collected during early recovery after 127. Verfaillie CM, Hurley R, Lundell BI, et al: Integrin-mediated regulation of hemato-
chemotherapy for chronic myeloid leukemia (CML). Bone Marrow Transplant 16:549, poiesis: Do BCR/ABL-induced defects in integrin function underlie the abnormal
1995. circulation and proliferation of CML progenitors? Acta Haematol 29:40, 1997.
100. Kirk JA, Reems JA, Roecklein BA, et al: Benign marrow progenitors are enriched 128. Symington BE: Growth signalling through the alpha 5 beta 1 fibronectin receptor.
in the CD34+/HLA-DRlo population but not in the CD34+/CD38lo population in Biochem Biophys Res Commun 208:126, 1995.
chronic myeloid leukemia: An analysis using interphase fluorescence in situ hybrid- 129. Bhatia R, McCarthy JB, Verfaillie CM: Interferon-alpha restores normal beta 1 inte-
ization. Blood 86:737, 1995. grin-mediated inhibition of hematopoietic progenitor proliferation by the marrow
101. Lewis ID, Haylock DN, Moore S, et al: Peripheral blood is a source of BCR-ABL– microenvironment in chronic myelogenous leukemia. Blood 87:3883, 1996.
negative pre-progenitors in early chronic phase chronic myeloid leukemia. Leukemia 130. Wertheim JA, Forsythe K, Druker BJ, et al: BCR-ABL-induced adhesion defects are
11:581, 1997. tyrosine kinase-independent. Blood 99:4122, 2002.
102. Maguer-Satta V, Petzer AL, Eaves AC, Eaves CJ: BCR-ABL expression in different sub- 131. Fruehauf S, Topaly J, Schad M, Paschka P, et al: Imatinib restores expression of CD62L
populations of functionally characterized Ph+ CD34+ cells from patients with chronic in BCR-ABL-positive cells. J Leukoc Biol 73:600, 2003.
myeloid leukemia. Blood 88:1796, 1996. 132. Salgia R, Li JL, Ewaniuk DS, et al: BCR/ABL induces multiple abnormalities of
103. Sirard C, Lapidot T, Vormoor J, et al: Normal and leukemia SCID-repopulating cells cytoskeletal function. J Clin Invest 100:46, 1997.
(SRC) coexist in the bone marrow and peripheral blood from CML patients in chronic 133. Lewis JM, Baskaran R, Taagepera S, et al: Integrin regulation of c-ABL tyrosine kinase
phase, whereas leukemic SRC are detected in blast crisis. Blood 87:1539, 1996. activity and cytoplasmic-nuclear transport. Proc Natl Acad Sci U S A 93:15174, 1996.
104. Dazzi F, Capelli D, Hasserjian R, et al: The kinetics and extent of engraftment of 134. Renshaw MW, McWhirter JR, Wang JY: The human leukemia oncogene bcr-abl abro-
chronic myelogenous leukemia cells in nonobese diabetic/severe combined immuno- gates the anchorage requirement but not the growth factor requirement for prolifera-
deficiency mice reflect the phase of the donor’s disease: An in vivo model for chronic tion. Mol Cell Biol 15:1286, 1995.
myelogenous leukemia biology. Blood 92:1390, 1998. 135. Salgia R, Brunkhorst B, Pisick E, et al: Increased tyrosine phosphorylation of focal
105. Holyoake TL, Jiang X, Drummond MW, et al: Elucidating critical mechanisms of adhesion proteins in myeloid cell lines expressing p210BCR/ABL. Oncogene 11:1149,
deregulated stem cell turnover in the chronic phase of chronic myelogenous leukemia. 1995.
Leukemia 16:549, 2002. 136. Rudkin GT, Hungerford DA, Nowell PC: DNA content of chromosome Ph1 and chro-
106. Eaves C, Cashman J, Eaves A: Defective regulation of leukemic hematopoiesis in mosome 21 in human chronic granulocytic leukemia. Science 144:1229, 1964.
chronic myeloid leukemia. Leuk Res 22:1085, 1998. 137. O’Riordan ML, Robinson JA, Buckton KE, Evans HJ: Distinguishing between the
107. Clarkson BD, Strife A, Wisniewski D, et al: New understanding of the pathogenesis of chromosome involved in Down’s syndrome (trisomy 21) and chronic myeloid leu-
CML: A prototype of early neoplasia. Leukemia 11:1404, 1997. kaemia (Ph1) by fluorescence. Nature 230:167, 1971.
108. Bedi A, Zehnbauer BA, Collector MI, et al: BCR-ABL gene rearrangement and expres- 138. Lawler SD: The cytogenetics of chronic granulocytic leukemia. Clin Haematol 6:55,
sion of primitive hematopoietic progenitors in chronic myeloid leukemia. Blood 1977.
81:2898, 1993. 139. Melo JV, Yan XH, Diamond J, Goldman JM: Balanced parental contribution to the
109. Moore MA: In vitro culture studies in chronic granulocytic leukaemia. Clin Haematol ABL component of the BCR-ABL gene in chronic myeloid leukemia. Leukemia 9:734,
6:97, 1977. 1995.
110. Sjögren U, Brandt L: Composition and mitotic activity of the erythropoietic part of the 140. Chissoe SL, Bodenteich A, Wang YF, et al: Sequence and analysis of the human ABL
bone marrow in chronic myeloid leukaemia. Scand J Haematol 12:18, 1974. gene, the BCR gene, and regions involved in the Philadelphia chromosomal translo-
111. Verfaillie CM: Stem cells in chronic myelogenous leukemia. Hematol Oncol Clin North cation. Genomics 27:67, 1995.
Am 11:1079, 1997. 141. Melo JV, Deininger MW: Biology of chronic myelogenous leukemia-signaling path-
112. Ghaffari S, Dougherty GJ, Lansdorp PM, et al: Differentiation-associated changes ways of initiation and transformation. Hematol Oncol Clin North Am 18:545, 2004.
in CD44 isoform expression during normal hematopoiesis and their alteration in 142. Daley GQ, Ben-Neriah Y: Implicating the bcr/abl gene in the pathogenesis of Philadel-
chronic myeloid leukemia. Blood 86:2976, 1995. phia chromosome-positive human leukemia. Adv Cancer Res 57:151, 1991.
113. Kawaishi K, Kimura A, Katch O, et al: Decreased L-selectin expression in CD34-positive 143. Heisterkamp N, Groffen J, Stephenson JR, et al: Chromosomal localization of human
cells from patients with chronic myelocytic leukaemia. Br J Haematol 93:367, 1996. cellular homologues of two viral oncogenes. Nature 299:747, 1982.
114. Turkina AG, Baryshnikov AY, Sedyakhina NP, et al: Studies of P-glycoprotein in 144. Heisterkamp N, Stephenson JR, Groffen J, et al: Localization of the c-abl oncogene
chronic myelogenous leukaemia patients: Expression, activity and correlations with adjacent to a translocation breakpoint in chronic myelocytic leukemia. Nature 306:
CD34 antigen. Br J Haematol 92:88, 1996. 239, 1983.
115. Agarwal R, Doren S, Hicks B, Dunbar CE: Long-term culture of chronic myelogenous 145. Konopka JB, Witte ON: Activation of the abl oncogene in murine and human leuke-
leukemia marrow cells on stem cell factor-deficient stroma favors benign progenitors. mias. Biochim Biophys Acta 823:1, 1985.
Blood 85:1306, 1995. 146. Collins SJ, Groudine MT: Rearrangements and amplification of c-abl sequences in the
116. Moore S, Haylock DN, Lévesque JP, et al: Stem cell factor as a single agent induces human chronic myelogenous leukemia cell line K562. Proc Natl Acad Sci U S A 80:
selective proliferation of the Philadelphia chromosome positive fraction of chronic 4813, 1983.
myeloid leukemia CD34+ cells. Blood 92:2461, 1998. 147. Canaani E, Gale RP, Steiner-Seltz D, et al: Altered transcription of an oncogene in
117. Chasty RC, Lucas GS, Owen-Lynch PJ, et al: Macrophage inflammatory protein-1 chronic myelocytic leukemia. Lancet 1:593, 1984.
alpha receptors are present on cells enriched for CD34 expression from patients with 148. Gale RP, Canaani E: An 8 kilobase abl RNA transcript in chronic myelogenous leuke-
chronic myeloid leukemia. Blood 86:4270, 1995. mia. Proc Natl Acad Sci U S A 81:5648, 1984.

Kaushansky_chapter 89_p1437-1490.indd 1475 9/18/15 3:42 PM